Logo image of ZEPP

ZEPP HEALTH CORP-ADR (ZEPP) Stock Fundamental Analysis

NYSE:ZEPP - New York Stock Exchange, Inc. - US98945L2043 - ADR - Currency: USD

25.33  +1.27 (+5.28%)

After market: 25.9222 +0.59 (+2.34%)

Fundamental Rating

2

Taking everything into account, ZEPP scores 2 out of 10 in our fundamental rating. ZEPP was compared to 124 industry peers in the Electronic Equipment, Instruments & Components industry. ZEPP may be in some trouble as it scores bad on both profitability and health. ZEPP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

ZEPP had negative earnings in the past year.
The reported net income has been mixed in the past 5 years: ZEPP reported negative net income in multiple years.
In multiple years ZEPP reported negative operating cash flow during the last 5 years.
ZEPP Yearly Net Income VS EBIT VS OCF VS FCFZEPP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

The Return On Assets of ZEPP (-15.60%) is worse than 68.55% of its industry peers.
The Return On Equity of ZEPP (-34.90%) is worse than 73.39% of its industry peers.
Industry RankSector Rank
ROA -15.6%
ROE -34.9%
ROIC N/A
ROA(3y)-8.27%
ROA(5y)-3.78%
ROE(3y)-16.67%
ROE(5y)-7.49%
ROIC(3y)N/A
ROIC(5y)N/A
ZEPP Yearly ROA, ROE, ROICZEPP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 -30

1.3 Margins

With a decent Gross Margin value of 38.83%, ZEPP is doing good in the industry, outperforming 67.74% of the companies in the same industry.
In the last couple of years the Gross Margin of ZEPP has grown nicely.
The Profit Margin and Operating Margin are not available for ZEPP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.57%
GM growth 5Y8.78%
ZEPP Yearly Profit, Operating, Gross MarginsZEPP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

3

2. Health

2.1 Basic Checks

ZEPP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ZEPP has less shares outstanding
Compared to 5 years ago, ZEPP has less shares outstanding
Compared to 1 year ago, ZEPP has a worse debt to assets ratio.
ZEPP Yearly Shares OutstandingZEPP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ZEPP Yearly Total Debt VS Total AssetsZEPP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ZEPP has an Altman-Z score of 3.15. This indicates that ZEPP is financially healthy and has little risk of bankruptcy at the moment.
ZEPP has a Altman-Z score of 3.15. This is comparable to the rest of the industry: ZEPP outperforms 54.84% of its industry peers.
A Debt/Equity ratio of 0.79 indicates that ZEPP is somewhat dependend on debt financing.
ZEPP has a Debt to Equity ratio of 0.79. This is amonst the worse of the industry: ZEPP underperforms 87.90% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z 3.15
ROIC/WACCN/A
WACC7.64%
ZEPP Yearly LT Debt VS Equity VS FCFZEPP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ZEPP has a Current Ratio of 1.14. This is a normal value and indicates that ZEPP is financially healthy and should not expect problems in meeting its short term obligations.
ZEPP's Current ratio of 1.14 is on the low side compared to the rest of the industry. ZEPP is outperformed by 88.71% of its industry peers.
A Quick Ratio of 0.84 indicates that ZEPP may have some problems paying its short term obligations.
ZEPP has a worse Quick ratio (0.84) than 85.48% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 0.84
ZEPP Yearly Current Assets VS Current LiabilitesZEPP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

1

3. Growth

3.1 Past

ZEPP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.53%, which is quite impressive.
The Revenue for ZEPP has decreased by -42.69% in the past year. This is quite bad
Measured over the past years, ZEPP shows a decrease in Revenue. The Revenue has been decreasing by -8.53% on average per year.
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-42.69%
Revenue growth 3Y-27.67%
Revenue growth 5Y-8.53%
Sales Q2Q%46.18%

3.2 Future

The Earnings Per Share is expected to grow by 39.51% on average over the next years. This is a very strong growth
Based on estimates for the next years, ZEPP will show a very negative growth in Revenue. The Revenue will decrease by -22.19% on average per year.
EPS Next Y85.63%
EPS Next 2Y39.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-49.23%
Revenue Next 2Y-22.19%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ZEPP Yearly Revenue VS EstimatesZEPP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B
ZEPP Yearly EPS VS EstimatesZEPP Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZEPP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZEPP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZEPP Price Earnings VS Forward Price EarningsZEPP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZEPP Per share dataZEPP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as ZEPP's earnings are expected to grow with 39.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.51%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ZEPP!.
Industry RankSector Rank
Dividend Yield N/A

ZEPP HEALTH CORP-ADR

NYSE:ZEPP (8/6/2025, 5:05:00 PM)

After market: 25.9222 +0.59 (+2.34%)

25.33

+1.27 (+5.28%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)08-03 2025-08-03/bmo
Earnings (Next)11-17 2025-11-17
Inst Owners28.98%
Inst Owner Change-13.58%
Ins Owners5.91%
Ins Owner ChangeN/A
Market Cap1.52B
Analysts82.86
Price Target12.57 (-50.38%)
Short Float %4.39%
Short Ratio0.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.18%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.36
P/FCF N/A
P/OCF N/A
P/B 6.55
P/tB 7.32
EV/EBITDA N/A
EPS(TTM)-8.57
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.03
BVpS3.87
TBVpS3.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.6%
ROE -34.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.83%
FCFM N/A
ROA(3y)-8.27%
ROA(5y)-3.78%
ROE(3y)-16.67%
ROE(5y)-7.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.57%
GM growth 5Y8.78%
F-ScoreN/A
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 0.84
Altman-Z 3.15
F-ScoreN/A
WACC7.64%
ROIC/WACCN/A
Cap/Depr(3y)22.81%
Cap/Depr(5y)96.65%
Cap/Sales(3y)0.51%
Cap/Sales(5y)0.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y85.63%
EPS Next 2Y39.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-42.69%
Revenue growth 3Y-27.67%
Revenue growth 5Y-8.53%
Sales Q2Q%46.18%
Revenue Next Year-49.23%
Revenue Next 2Y-22.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-103.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-162.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-156.9%
OCF growth 3YN/A
OCF growth 5YN/A